<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04842812</url>
  </required_header>
  <id_info>
    <org_study_id>TILs on cancers</org_study_id>
    <nct_id>NCT04842812</nct_id>
  </id_info>
  <brief_title>Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors</brief_title>
  <official_title>Engineered TILs/CAR-TILs With PD1 Knockout and Anti-PD1/CTLA4-scFv Secreting or CARs Against Various Antigens to Treat Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Zhaotai InVivo Biomedicine Co. Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital of Guangzhou Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Tumor infiltration lymphocytes (TILs) have been harvested from advanced cancer patients and&#xD;
      constructed to knockout PD1 gene and express scFvs against both PD1 and CTALA4 and CARs&#xD;
      against various antigens, followed by transfusion into the patients. The safety, tolerance,&#xD;
      and preliminary clinical efficacy of the TILs will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Choose appropriate patients with advanced lung or other cancers, with written consent&#xD;
           for this study;&#xD;
&#xD;
        2. Perform biopsy or collect cancerous effusion in thorax or abdomen to obtain TILs by&#xD;
           standard protocol;&#xD;
&#xD;
        3. Grow TILs and engineered the tumor-effective TILs with CRISPRA-CAS9 technique to&#xD;
           knockdown PD1 and electronic-transfection strategy to express scFvs that target PD1 and&#xD;
           CTLA4; amplify the engineered T cells as needed, test the quality and killing activity&#xD;
           of the TILs and then transfuse them back the patients via systemic or local injections&#xD;
           via standard protocol, and follow up closely to collect related parameters as needed;&#xD;
&#xD;
        4. To enhance the killing capability, tumor-noneffective TILs have also been genetically&#xD;
           engineered to express various CARs targeting HER2/Mesothelin/Lewis-Y/PSCA/MUC1/&#xD;
           GPC3/AXL/EGFR/Claudin18.2/B7-H3/ROR1/GD2/AXL/Claudin6-DAP10 with knockdown of PD1/HPK1&#xD;
           as appropriate;&#xD;
&#xD;
        5. Evaluate the clinical results as needed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2035</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>TILs treatment of solid cancers</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of TILs/CAR-TILs treatment in advanced solid cancers</measure>
    <time_frame>up to 36 months</time_frame>
    <description>Assessing Number of participants with treatment-related adverse events as assessed by CTCAE v4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Primary clinical efficacy of the TILs/CAR-TILs treatment in advanced solid cancers</measure>
    <time_frame>15 years</time_frame>
    <description>Assessing various clinical response rates including complete response, partial response, stable disease, and progress disease during and after TILs/CAR-TILs treatment in advanced solid cancers.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Liver Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Colo-rectal Cancer</condition>
  <condition>Brain Tumor</condition>
  <condition>Solid Tumor, Adult</condition>
  <condition>PD1</condition>
  <condition>CTLA4</condition>
  <arm_group>
    <arm_group_label>TILs/CAR-TILs treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Obtain TILs/CAR-TILs from advanced solid tumor patients and infuse them back to evaluate safety and clinical efficacy of the treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3</intervention_name>
    <description>TILs and CAR-TILs injection: 1-10Ã—10e7/kg cells for each treatment; 3 or more cycles.</description>
    <arm_group_label>TILs/CAR-TILs treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with advanced cancers that failed to current available therapies;&#xD;
&#xD;
          2. Life expectancy &gt;12 weeks;&#xD;
&#xD;
          3. Adequate heart, lung, liver, kidney functions;&#xD;
&#xD;
          4. Available for tumor biopsy or cancerous effusions;&#xD;
&#xD;
          5. Informed consent explained to, understood by and signed by patient/guardian.&#xD;
             Patient/guardian given copy of informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Had accepted gene therapy before;&#xD;
&#xD;
          2. Severe virus infection such as HBV, HCV, HIV, et al; Known HIV positivity;&#xD;
&#xD;
          3. Active infectious disease related to bacteria, virus, fungi, et al;&#xD;
&#xD;
          4. Other severe diseases that the investigators consider not appropriate;&#xD;
&#xD;
          5. Pregnant or lactating women;&#xD;
&#xD;
          6. Systemic steroid treatment (greater than or equal to 0.5 mg prednisone&#xD;
             equivalent/kg/day);&#xD;
&#xD;
          7. Other conditions that the investigators consider not appropriate.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhenfeng Zhang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenfeng Zhang, MD, PhD</last_name>
    <phone>+862039195966</phone>
    <email>zhangzhf@gzhmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bingjia He, MD</last_name>
    <phone>+862039195965</phone>
    <email>464677938@qq.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510260</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenfeng Zhang, MD, PhD</last_name>
      <phone>+862039195966</phone>
      <email>zhangzhf@gzhmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Bingjia He</last_name>
      <phone>+862039195965</phone>
      <email>464677938@qq.com</email>
    </contact_backup>
    <investigator>
      <last_name>Zhenfeng Zhang, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peng Li, PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 4, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>liver Cancer</keyword>
  <keyword>Lung Cancer</keyword>
  <keyword>Solid Tumor</keyword>
  <keyword>TIL</keyword>
  <keyword>CAR-TIL</keyword>
  <keyword>PD1</keyword>
  <keyword>CTLA4</keyword>
  <keyword>GPC3</keyword>
  <keyword>Mesothelin</keyword>
  <keyword>B7-H3</keyword>
  <keyword>CRISPRA-CAS9</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

